307 related articles for article (PubMed ID: 30795773)
1. Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1-98.
Kensler KH; Regan MM; Heng YJ; Baker GM; Pyle ME; Schnitt SJ; Hazra A; Kammler R; Thürlimann B; Colleoni M; Viale G; Brown M; Tamimi RM
Breast Cancer Res; 2019 Feb; 21(1):30. PubMed ID: 30795773
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
Rasmussen BB; Regan MM; Lykkesfeldt AE; Dell'Orto P; Del Curto B; Henriksen KL; Mastropasqua MG; Price KN; Méry E; Lacroix-Triki M; Braye S; Altermatt HJ; Gelber RD; Castiglione-Gertsch M; Goldhirsch A; Gusterson BA; Thürlimann B; Coates AS; Viale G;
Lancet Oncol; 2008 Jan; 9(1):23-8. PubMed ID: 18083065
[TBL] [Abstract][Full Text] [Related]
3. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.
Regan MM; Neven P; Giobbie-Hurder A; Goldhirsch A; Ejlertsen B; Mauriac L; Forbes JF; Smith I; Láng I; Wardley A; Rabaglio M; Price KN; Gelber RD; Coates AS; Thürlimann B; ;
Lancet Oncol; 2011 Nov; 12(12):1101-8. PubMed ID: 22018631
[TBL] [Abstract][Full Text] [Related]
4. Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial.
Luen SJ; Asher R; Lee CK; Savas P; Kammler R; Dell'Orto P; Biasi OM; Demanse D; JeBailey L; Dolan S; Hackl W; Thuerlimann B; Viale G; Colleoni M; Regan MM; Loi S
JAMA Oncol; 2018 Oct; 4(10):1335-1343. PubMed ID: 29902286
[TBL] [Abstract][Full Text] [Related]
5. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
[TBL] [Abstract][Full Text] [Related]
6. Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer.
Giobbie-Hurder A; Price KN; Gelber RD; ;
Clin Trials; 2009 Jun; 6(3):272-87. PubMed ID: 19528136
[TBL] [Abstract][Full Text] [Related]
7. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
[TBL] [Abstract][Full Text] [Related]
8. Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial.
Bartlett JMS; Sgroi DC; Treuner K; Zhang Y; Ahmed I; Piper T; Salunga R; Brachtel EF; Pirrie SJ; Schnabel CA; Rea DW
Ann Oncol; 2019 Nov; 30(11):1776-1783. PubMed ID: 31504126
[TBL] [Abstract][Full Text] [Related]
9. Update of the BIG 1-98 Trial: where do we stand?
Joerger M; Thürlimann B
Breast; 2009 Oct; 18 Suppl 3():S78-82. PubMed ID: 19914548
[TBL] [Abstract][Full Text] [Related]
10. Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial.
Ewertz M; Gray KP; Regan MM; Ejlertsen B; Price KN; Thürlimann B; Bonnefoi H; Forbes JF; Paridaens RJ; Rabaglio M; Gelber RD; Colleoni M; Láng I; Smith IE; Coates AS; Goldhirsch A; Mouridsen HT
J Clin Oncol; 2012 Nov; 30(32):3967-75. PubMed ID: 23045588
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial.
Ruhstaller T; Giobbie-Hurder A; Colleoni M; Jensen MB; Ejlertsen B; de Azambuja E; Neven P; Láng I; Jakobsen EH; Gladieff L; Bonnefoi H; Harvey VJ; Spazzapan S; Tondini C; Del Mastro L; Veyret C; Simoncini E; Gianni L; Rochlitz C; Kralidis E; Zaman K; Jassem J; Piccart-Gebhart M; Di Leo A; Gelber RD; Coates AS; Goldhirsch A; Thürlimann B; Regan MM;
J Clin Oncol; 2019 Jan; 37(2):105-114. PubMed ID: 30475668
[TBL] [Abstract][Full Text] [Related]
12. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.
Viale G; Regan MM; Maiorano E; Mastropasqua MG; Dell'Orto P; Rasmussen BB; Raffoul J; Neven P; Orosz Z; Braye S; Ohlschlegel C; Thürlimann B; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
J Clin Oncol; 2007 Sep; 25(25):3846-52. PubMed ID: 17679725
[TBL] [Abstract][Full Text] [Related]
13. Androgen receptor expression in male breast cancer predicts inferior outcome and poor response to tamoxifen treatment.
Wenhui Z; Shuo L; Dabei T; Ying P; Zhipeng W; Lei Z; Xiaohui H; Jingshu G; Hongtao S; Qingyuan Z
Eur J Endocrinol; 2014 Oct; 171(4):527-33. PubMed ID: 25069458
[TBL] [Abstract][Full Text] [Related]
14. Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study.
Colleoni M; Giobbie-Hurder A; Regan MM; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Láng I; Smith I; Chirgwin J; Pienkowski T; Wardley A; Price KN; Gelber RD; Coates AS; Goldhirsch A
J Clin Oncol; 2011 Mar; 29(9):1117-24. PubMed ID: 21321298
[TBL] [Abstract][Full Text] [Related]
15. Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial.
Mamounas EP; Bandos H; Lembersky BC; Jeong JH; Geyer CE; Rastogi P; Fehrenbacher L; Graham ML; Chia SK; Brufsky AM; Walshe JM; Soori GS; Dakhil SR; Seay TE; Wade JL; McCarron EC; Paik S; Swain SM; Wickerham DL; Wolmark N
Lancet Oncol; 2019 Jan; 20(1):88-99. PubMed ID: 30509771
[TBL] [Abstract][Full Text] [Related]
16. Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial.
Dar H; Johansson A; Nordenskjöld A; Iftimi A; Yau C; Perez-Tenorio G; Benz C; Nordenskjöld B; Stål O; Esserman LJ; Fornander T; Lindström LS
JAMA Netw Open; 2021 Jun; 4(6):e2114904. PubMed ID: 34190995
[TBL] [Abstract][Full Text] [Related]
17. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
18. Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials.
Regan MM; Pagani O; Francis PA; Fleming GF; Walley BA; Kammler R; Dell'Orto P; Russo L; Szőke J; Doimi F; Villani L; Pizzolitto S; Öhlschlegel C; Sessa F; Peg Cámara V; Rodríguez Peralto JL; MacGrogan G; Colleoni M; Goldhirsch A; Price KN; Coates AS; Gelber RD; Viale G;
Breast Cancer Res Treat; 2015 Nov; 154(2):275-86. PubMed ID: 26493064
[TBL] [Abstract][Full Text] [Related]
19. Higher expression of androgen receptor is a significant predictor for better endocrine-responsiveness in estrogen receptor-positive breast cancers.
Park S; Park HS; Koo JS; Yang WI; Kim SI; Park BW
Breast Cancer Res Treat; 2012 May; 133(1):311-20. PubMed ID: 22231421
[TBL] [Abstract][Full Text] [Related]
20. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.
Regan MM; Leyland-Jones B; Bouzyk M; Pagani O; Tang W; Kammler R; Dell'orto P; Biasi MO; Thürlimann B; Lyng MB; Ditzel HJ; Neven P; Debled M; Maibach R; Price KN; Gelber RD; Coates AS; Goldhirsch A; Rae JM; Viale G;
J Natl Cancer Inst; 2012 Mar; 104(6):441-51. PubMed ID: 22395644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
